Comparison of clinical manifestations and laboratory features between AML patients with and without WT1 mutation
| Variable . | Total (n = 470) . | WT1-mutated (n = 32, 6.8%) . | WT1-wild (n = 438, 93.2%) . | P . |
|---|---|---|---|---|
| Sex, no. (%) of patients | .250 | |||
| Male | 266 | 15 (46.9) | 251 (57.3) | — |
| Female | 204 | 17 (53.1) | 187 (42.7) | — |
| Median age, y (range) | 52.0 (15-90) | 38.5 (15-85) | 53 (15-90) | < .001 |
| Laboratory data, median (range) | ||||
| WBCs, per μL | 21 850 (120-627 800) | 20 290 (1200-227 700) | 21 850 (120-627 800) | .785 |
| Hemoglobin, g/dL | 8.0 (2.9-16.2) | 7.65 (3-13.6) | 8 (2.9-16.2) | .468 |
| Platelets, × 1000/μL | 45.0 (3-802) | 46.5 (7-802) | 44 (3-802) | .653 |
| Blasts, per μL | 9863 (0-456 725) | 9927 (120-154 836) | 9863 (0-456 725) | .928 |
| LDH, U/L | 890 (206-15 000) | 1228 (301-7734) | 856 (206-15 000) | .107 |
| FAB, no. (%) of patients | .017 | |||
| M0 | 10 | 0 (0.0) | 10 (100.0) | — |
| M1 | 114 | 6 (5.3) | 108 (94.7) | — |
| M2 | 174 | 16 (9.2) | 158 (90.8) | — |
| M4 | 126 | 4 (3.2) | 122 (96.8) | — |
| M5 | 25 | 1 (4.0) | 24 (96.0) | — |
| M6 | 12 | 4 (33.3) | 8 (66.7) | — |
| Undetermined | 9 | 1 (11.1) | 8 (88.9) | — |
| Induction response* | 330 | 28 | 302 | .516 |
| CR | 248 (75.2) | 21 (75.0) | 227 (75.2) | — |
| Refractory | 59 (17.8) | 6 (21.4) | 53 (17.5) | — |
| Induction death | 23 (7.0) | 1 (3.6) | 22 (7.3) | — |
| Relapse | 134 (54.0) | 18 (85.7) | 116 (51.1) | .002 |
| Variable . | Total (n = 470) . | WT1-mutated (n = 32, 6.8%) . | WT1-wild (n = 438, 93.2%) . | P . |
|---|---|---|---|---|
| Sex, no. (%) of patients | .250 | |||
| Male | 266 | 15 (46.9) | 251 (57.3) | — |
| Female | 204 | 17 (53.1) | 187 (42.7) | — |
| Median age, y (range) | 52.0 (15-90) | 38.5 (15-85) | 53 (15-90) | < .001 |
| Laboratory data, median (range) | ||||
| WBCs, per μL | 21 850 (120-627 800) | 20 290 (1200-227 700) | 21 850 (120-627 800) | .785 |
| Hemoglobin, g/dL | 8.0 (2.9-16.2) | 7.65 (3-13.6) | 8 (2.9-16.2) | .468 |
| Platelets, × 1000/μL | 45.0 (3-802) | 46.5 (7-802) | 44 (3-802) | .653 |
| Blasts, per μL | 9863 (0-456 725) | 9927 (120-154 836) | 9863 (0-456 725) | .928 |
| LDH, U/L | 890 (206-15 000) | 1228 (301-7734) | 856 (206-15 000) | .107 |
| FAB, no. (%) of patients | .017 | |||
| M0 | 10 | 0 (0.0) | 10 (100.0) | — |
| M1 | 114 | 6 (5.3) | 108 (94.7) | — |
| M2 | 174 | 16 (9.2) | 158 (90.8) | — |
| M4 | 126 | 4 (3.2) | 122 (96.8) | — |
| M5 | 25 | 1 (4.0) | 24 (96.0) | — |
| M6 | 12 | 4 (33.3) | 8 (66.7) | — |
| Undetermined | 9 | 1 (11.1) | 8 (88.9) | — |
| Induction response* | 330 | 28 | 302 | .516 |
| CR | 248 (75.2) | 21 (75.0) | 227 (75.2) | — |
| Refractory | 59 (17.8) | 6 (21.4) | 53 (17.5) | — |
| Induction death | 23 (7.0) | 1 (3.6) | 22 (7.3) | — |
| Relapse | 134 (54.0) | 18 (85.7) | 116 (51.1) | .002 |
— indicates not applicable.
Only the 330 patients (including 28 with the WT1 mutation and 302 without) who received conventional intensive induction chemotherapy and then consolidation chemotherapy if CR was achieved, were included in the analysis.